spacer
home > ict > winter 2008 > patients are a virtue
PUBLICATIONS
International Clinical Trials

Patients Are a Virtue

Considering whether less haste in the short-term might actually improve speed-to-market, Mike Macnamee of LCG Bioscience urges the incorporation of patient studies into early stage clinical research

Although it is clear that there are many benefits of using patients in the early stages of clinical trials, it is also evident from recent discussions between sponsors and researchers that the use of patients before Phase II is still very limited. One of the reasons for this is that patient studies can be more time consuming to conduct, and this is an industry driven by speed. Additionally, while volunteer trials are well understood and the outcomes easily interpreted, patient trials are a new departure and generate a wealth of data that can create uncertainty in interpretation for both sponsor and regulatory authorities.

STOPPING EARLY STAGE TRIALS

One of the most effective ways in which pharmaceutical companies can hope to improve the efficiency of their development programmes is to terminate any project that is destined to fail as soon as possible. However, it is difficult in traditional drug development to distinguish winners from losers. And although it is late stage failures that cause the most angst for drug developers, there could be just as many promising compounds with useful indications that are dropped at the early stages because there is insufficient evidence of biological activity to justify the risk versus benefit ratio of their progression through the regulatory process.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Mike Macnamee is Chief Executive of LCG Bioscience, a provider of exploratory clinical research in volunteers and patient populations to the biotech and pharma industry. A graduate from Edinburgh in 1979 with a BSc in Psychology, he then gained an MSc in Pharmacology at London University, before returning to Edinburgh to complete his doctorate in Neuropharmacology (1984) at the Rosalin Institute. Mike founded LCG in 1993 and went on to create the Research Medicine Group for Serono. He has extensive experience in the development of both biological and chemical compounds targeting debilitating disease and has worked extensively across disciplines and cultures internationally. He led LCG to full independence through a successful MBO in 2005.
spacer
Dr Mike Macnamee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers
 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement